F
Fate Therapeutics Inc.
Biotechnology: Biological Products (No Diagnostic Substances) company
Key Metrics of Fate Therapeutics Inc.
Revenue$63.5M▼ 34.0% YoYFY 2023
Operating income−$191M▲ 38.2% YoY
Net profit−$161M▲ 42.9% YoY
Shareholders' equity$368M
Market cap$249MFATE · $2.08
Competitors10identified
About Fate Therapeutics Inc.
Sectors
Company details
- Founded
- 2013
- Listed
- Nasdaq: FATE (since 2013)
Operational Areas of Fate Therapeutics Inc.
Pharmaceuticals & Healthcare›Biotechnology & Vaccines
Company summary
Legal nameFate Therapeutics Inc.
TickerFATE
ExchangeNasdaq
CountryUnited States
SEC CIK0001434316
Listed since2013
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
SectorPharmaceuticals & Healthcare · Biotechnology & Vaccines
Website—
US market & SEC filings
FATE · Nasdaq · SEC CIK 0001434316
Last price · 02 Nov 2026
$2.08
−4.15%
Market cap$249M
P/E—On FY 2023 diluted EPS
Volume1,064,428
SectorHealth CareBiotechnology: Biological Products (No Diagnostic Substances)
Country · IPOUnited StatesListed 2013
FATE share price
Premium
Annual results (SEC EDGAR)
Revenue, operating income, net income, EPS, cash flow, assets, liabilities, equity and debt for every year filed with the SEC are part of the premium plan.
Sign in to continue See plans & pricingVendor checks & payment capacity
Sign in with access to company financials to review vendor evidence.
Registered office and contact
Registered office—
GSTIN—
Email—
Website—
Members / shareholders—
Directors and key people
Directors are read from the MGT-7 annual return and AOC-4 signatories.
Competitors of Fate Therapeutics Inc.
Competitors10identified
Countries1most in United States
Top competitors by location
| Company | Description | Domain | Founded | Location |
|---|---|---|---|---|
| Part of Vertex Pharmaceuticals. | vrtx.com | 1991 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | modernatx.com | 2018 | United States | |
 Becton Dickinson |
Biotechnology & Vaccines · Pharmaceuticals & Healthcare | bd.com | — | United States |
| Part of Illumina. | illumina.com | 2000 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | guardanthealth.com | 2018 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | revvity.com | — | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | exelixis.com | 2000 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | neurocrine.com | 1996 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | biomarin.com | 1999 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | twistbioscience.com | 2018 | United States |
Charges (secured borrowings)
0 registered charges. Lenders, amounts and dates are part of the premium plan.
Statutory auditors
Auditors are read from the AOC-4 auditor's report section.
Business activities and related parties
Principal business activities and related-party transactions are read from MGT-7 and AOC-4 filings.
Filings
No filings on record yet.